Cadiz, Inc., a California water solutions company, announced a cash dividend of $560 per whole share on its 8.875% Series A Cumulative Perpetual Preferred Stock. Depositary shares, representing fractional interests, will receive $0.56 per share. The dividend will be paid on October 15, 2026, to shareholders recorded by October 5, 2026. This dividend reflects Cadiz's ongoing commitment to returning value to its preferred shareholders amid its water supply and treatment operations in California.
Cadiz Inc.'s announcement of a quarterly dividend on its Series A Cumulative Perpetual Preferred Stock provides context for readers interested in dividend-paying securities. For readers following the Utilities sector, here is Pluang's market snapshot as of Sep 25, 2026 19:12 WIB: Among 22 priced US Utilities stocks on Pluang, 14 rose and 7 fell. Notable movers include NRG Energy Inc at USD 98.86 with a 1.03% increase and 100% buy order activity, Vistra Corp at USD 139.33 up 1.01% with 81% buy orders, and Oklo Inc at USD 38.62 rising 0.86% with 81% buy orders.
Assured Guaranty Ltd. (NYSE: AGO) saw its stock price pressured to a new 52-week low of $68.04 despite a recent upgrade to "Buy" by Roth Capital. The company is involved in the financial restructuring of Brightline Florida, where a subsidiary insured...
Legacy Education Inc. reported Q4 2026 earnings with an EPS of $0.13, missing analyst estimates of $0.15, and revenue of $20.1 million, slightly below expectations. Despite this, the company achieved a 12% year-over-year revenue increase in Q4 and a ...
Carnival Corporation & plc is set to report Q3 earnings with analysts forecasting $8.39 billion in revenue and $1.36 EPS, reflecting a 4.9% decline from last year. The company's stock has dropped 27% recently due to a 30% surge in Brent oil prices, w...
Oklo, a pre-revenue nuclear tech company, is developing advanced small modular reactors (SMRs) called Aurora Powerhouses aimed at clean energy for data centers. UBS set a price target of $41, indicating a 7.08% upside from the current $38.29 stock pr...
Barclays initiated coverage on Ligand Pharmaceuticals with an 'Overweight' rating and set a price target of $345, implying a 15.37% upside from its current price. The biopharma company is expanding its royalty portfolio through investments in cancer ...
